We’re pleased to announce that Emergent portfolio company, Caisson Biotech, LLC, received a nomination for the 2014 Buzz of BIO Award in the Technologies of Tomorrow category.
This contest is intended to identify the most innovative biotech companies that are R&D-intensive and are developing strategic partnerships within the industry. Caisson’s novel drug delivery technology and recent deals with Novo Nordisk make it a perfect nominee for this award.
We need your help to make it to the Winners’ circle.
Please vote for Caisson Biotech, LLC, in the Technologies of Tomorrow category today, April 15th, and everyday through April 22nd. That’s right — supporters may cast one vote per day for their favorite biotech company.
Why vote for Caisson Biotech?
Caisson has developed a patented heparosan-based drug delivery technology that will improve the performance of drug compounds in terms of safety, tolerability, efficacy, and quality. The technology has potential to greatly improve treatment efficacy for diabetes patients and patients with other long-term or life-long diseases including:
- Obesity
- Inflammatory disease (such as Crohn’s, lupas, rheumatoid and psoriatic arthritis)
- Chronic illnesses requiring human growth hormone therapy
These represent only a few therapeutic areas where this ground-breaking technology holds great potential to not only help patients, but also give industry partners a way to protect and grow their core businesses.
What happens after you help us win? We will have the opportunity to give a company presentation at the BIO Business Forum in front of other influential industry leaders along with a free pass to the show. So, please, vote now and don’t forget to come back to cast another vote for Caisson in Technologies of Tomorrow everyday through April 22nd. Take me to the voting booth!
I’d like to thank you in advance for helping us win the title of best innovative biotech company, on behalf of the entire Emergent Technologies team. What do you want to build today?